Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces Licensing Agreement with XenaCare Holdings to Market and Distribute Cobroxin, a Treatment for Chronic Pain
August 26, 2009

Nutra Pharma has announced that it has completed a licensing agreement that grants XenaCare Holdings the exclusive marketing and distribution rights to Cobroxin within the United States. Cobroxin is a recently launched over-the-counter (OTC) pain reliever for treating chronic pain.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

“We are pleased to be working with XenaCare as our exclusive US marketing and distribution licensee for Cobroxin,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “For the past several months, XenaCare has continued to commit significant time, industry expertise and financial resources towards the launch of Cobroxin. We look forward to working closely with them as they complete the initial roll-out of Cobroxin to retailers across the country,” he added.

Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.

Additional benefits to Cobroxin include:

  • All Natural
  • Non-Addictive
  • Non-Narcotic
  • Non-Opiate
  • More Potent than Morphine
  • Long Lasting

“Cobroxin is a unique pain reliever that we believe can help improve the lives of the millions of Americans who are actively seeking a safer and more effective alternative for treating chronic pain,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “We have already committed millions of dollars and industry resources towards the launch of Cobroxin and will continue to do so as we successfully introduce Cobroxin through retailers this fall,” he concluded.

On Monday, Nutra Pharma announced that it had completed submission of final Cobroxin packaging and labeling to the Food and Drug Administration (FDA). This submission was the final step required to begin selling Cobroxin.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Completing the agreement with XenaCare Holdings for marketing and distributing Cobroxin should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics